Plantain

Metadata

Approved Indications

German Commission E

• Internal: Catarrh of the airways
• Internal: Inflammatory changes of the mucous membranes of the mouth and throat

ESCOP

• Internal: Catarrh of the respiratory tract
• Demulcent for irritation of the oral and pharyngeal mucosa

EMA/HMPC

• Traditional use: Relief of symptoms of common cold, such as sore throat and dry cough
• Traditional herbal medicinal product classification (not well-established use)

Agreement/Disagreement Between Bodies

Commission E and ESCOP are closely aligned. The EMA places plantain in the “traditional use” category, which reflects the limited clinical trial evidence despite long historical use. All bodies agree on the respiratory catarrh indication.

Conditions Treated

• Respiratory catarrh (primary)
• Irritative/dry cough
• Chronic irritative cough (especially in children)
• Sore throat and pharyngeal inflammation
• Oral mucosal inflammation
• Mild upper respiratory tract infections

Mechanism of Action

1. Demulcent/Mucoprotective (Mucilage)

• Mucilage polysaccharides compose up to 10% of dry leaf weight
• Form a protective viscous layer over irritated mucous membranes
• Soothe the cough reflex by coating the pharyngeal and laryngeal mucosa
• Similar mechanism to marshmallow (Althaea officinalis), though different polysaccharide composition

2. Anti-inflammatory (Iridoid Glycosides)

• Aucubin (1-3% in dried leaf): Demonstrates both anti-inflammatory and antibacterial activity
  • Inhibits growth of Staphylococcus aureus and Streptococcus pyogenes in vitro
  • Anti-inflammatory mechanism involves COX-2 inhibition and NF-kB modulation
• Catalpol (up to 1%): Additional anti-inflammatory properties
• Iridoid content varies with leaf maturity: young leaves contain up to 9% total iridoids (catalpol-dominant); older leaves have lower content (aucubin-dominant)

3. Antibacterial

• Aucubin and its aglycone aucubigenin have demonstrated activity against respiratory pathogens
• Plantamajoside and acteoside (phenylethanoid glycosides) contribute additional antibacterial effects

4. Spasmolytic

• Mild spasmolytic activity on bronchial smooth muscle demonstrated in vitro

5. Immunostimulant

• In vitro studies suggest immunostimulant properties, though mechanism is not fully characterized

Key Active Constituents

• Mucilage polysaccharides (up to 10% of dry weight)
• Iridoid glycosides: Aucubin (1-3%), catalpol (up to 1%)
• Phenylethanoid glycosides: Acteoside (verbascoside), isoacteoside, plantamajoside
• Flavonoids: Apigenin, luteolin
• Phenolic acids: Chlorogenic acid, vanillic acid, caffeic acid
• Tannins
• Saponins (minor)

Bioavailability Note

Aucubin has low oral bioavailability (~19.3%) due to instability at gastric pH (half-life 5.1-14.8 hours at pH 1.2-2.0) and limited gastrointestinal absorption with extensive first-pass metabolism. This may limit the systemic anti-inflammatory effects of oral preparations, though the local (topical mucosal) effects of mucilage are not affected by bioavailability.

Clinical Evidence Summary

Available Clinical Data

• Open clinical study: Ribwort plantain extract in patients with respiratory tract catarrh — showed improvement in symptoms [NEEDS-RESEARCH: Study details, sample size, and methodology not fully available from current sources]
• No large, well-designed, placebo-controlled RCTs identified specifically for Plantago lanceolata monotherapy in respiratory conditions
• Plantago major (a related species): One double-blind RCT for acute bronchitis showed benefit in cough severity (PMC 11444096), but this is a different species

In Vitro and Preclinical Evidence

The experimental evidence is considerably stronger than the clinical evidence:

• Anti-inflammatory activity confirmed in multiple in vitro models
• Antibacterial activity against respiratory pathogens (S. aureus, S. pyogenes, H. influenzae)
• Antiviral activity demonstrated
• Spasmolytic activity on bronchial smooth muscle
• Immunostimulant activity observed
• Antioxidant properties confirmed

Expert Assessment

Despite limited clinical trial data, a positive benefit-risk ratio allows recommendation of plantain for moderate chronic irritative cough, especially for children, where the safety profile and mucilage-based mechanism make it particularly suitable.

Evidence Limitations

• Clinical evidence base is weak by modern standards
• Most evidence is preclinical/in vitro
• No head-to-head comparisons with standard treatments
• Traditional use evidence supports efficacy but does not meet current RCT standards

European vs. US/Anglophone Consensus

Notable cultural gap: Plantago lanceolata is one of the herbs where the gap between German/European and Anglophone use is most pronounced. In Germany, it was named “Medicinal Plant of the Year 2014” by the Study Group for the History of Medicine. In Anglophone countries, it is typically regarded only as a lawn weed.

Safety Profile

Contraindications

• Hypersensitivity to Plantago lanceolata or other Plantaginaceae
• No other contraindications known

Drug Interactions

• No known drug interactions
• Mucilage may theoretically slow absorption of other oral medications if taken simultaneously (general mucilage caution; not specifically studied for plantain)

Side Effects

• Very few adverse events reported
• Minor gastrointestinal disturbance possible but rare
• Exceptionally good safety profile, which makes it particularly suitable for children

Pregnancy and Lactation

• Pregnancy: No specific concerns identified; traditional use during pregnancy has occurred without reported problems. However, formal safety studies are lacking.
• Lactation: No specific concerns identified.
• [UNCERTAIN: Formal safety assessment in pregnancy/lactation is incomplete]

Toxicology

• Maximum aucubin doses of 800 mg/kg body weight 4 times weekly in animal studies did not cause significant changes in liver transaminases, alkaline phosphatase, triglycerides, glucose, blood urea nitrogen, or total protein
• Considered non-toxic at therapeutic doses

Clinical Dosage

Herbal Tea (Infusion)

Pressed Juice

Syrup/Fluid Extract

• Commercial preparations (e.g., Spitzwegerich Hustensaft/cough syrup): Follow product-specific dosing
• Typically suitable for children from age 1-2 years (depending on product)

Duration

• Acute use: 7-14 days
• Can be used for longer periods for chronic irritative cough given safety profile

Sources

• German Commission E Monograph: Plantaginis lanceolatae herba/folium
• ESCOP Monograph: Plantaginis lanceolatae folium-herba
• EMA/HMPC Assessment Report on Plantago lanceolata L., folium
• Altmeyers Encyclopedia: Plantaginis lanceolatae herba entry
• Arzneipflanzenlexikon.info: Ribwort Plantain monograph
• Wegener & Kraft (1999). Plantain anti-inflammatory action in URTI. PubMed 10483683.
• ScienceDirect: Plantago lanceolata overview topic
• PMC 10237569: In vitro evaluation of P. lanceolata root fractions

Connections

• Compare demulcent mechanism with Marshmallow (Althaea officinalis)
• Compare evidence level with Linden Flower (both traditional use category)